TKIs

DRUG4 trials

Sponsors

Nanfang Hospital, Southern Medical University, The First Affiliated Hospital with Nanjing Medical University, Novartis Pharmaceuticals

Conditions

Breast CancerChronic Myelogenous Leukemia - Chronic PhaseLeukemia, Lymphoblastic, AcuteMinimal Residual DiseasePhiladelphia Chromosome Positive Acute Lymphocytic LeukemiaStem Cell Transplantation

Phase 2

TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Nanfang Hospital, Southern Medical UniversityMinimal Residual Disease, Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation

Start: 2013-06-30End: 2017-11-30Target: 80Updated: 2017-11-08

Unknown Phase

Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia

Nanfang Hospital, Southern Medical UniversityLeukemia, Lymphoblastic, Acute

Start: 2017-11-01End: 2019-09-01Target: 100Updated: 2017-11-08

Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study

The First Affiliated Hospital with Nanjing Medical UniversityBreast Cancer

Start: 2019-08-01End: 2022-12-31Target: 100Updated: 2022-02-09

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

RecruitingNCT07091019

Novartis PharmaceuticalsChronic Myelogenous Leukemia - Chronic Phase

Start: 2025-12-17End: 2033-04-20Target: 1000Updated: 2026-07-20

Related Papers

A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study.

2020-11-1720 citations